EGFR A859T

CI-VAR-00000148Explore in graph →NP_005219.2:p.Ala859ThrNM_005228.3:c.2575G>ACIViC 1474

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR A859T	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4297 In a lung adenocarcinoma patient harboring EGFR A859T mutation, EGFR A859T was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy and subsequ… (full text at CIViC) PMID 21317745 · Le Maignan et al., 2011 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
EGFR A859T	Erlotinib	Predictive	D	Supports Resistance	—	submitted	EID4296 In an in vitro study, a MCF-7 cell line expressing EGFR A859T demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGF… (full text at CIViC) PMID 17877814 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.